ExceeMatrix

Company Overview

Snapshot

Founded in March 2012, ExceeMatrix operates with 1–10 employees. The company presented promising results for its ACL implant in an animal study in February 2016.

Business overview

ExceeMatrix develops high-strength collagen medical devices utilizing fibers derived from soft corals, which possess tensile strength superior to human connective tissue. The company employs a proprietary technology platform to create regenerative implants with high mechanical properties, serving the medical devices and biomaterials sectors within the Health Tech & Life Sciences industry.

Strategic signal

In February 2016, ExceeMatrix announced promising results from an animal study for its ACL implant. This development signals potential for advancing regenerative medicine and orthopedic solutions, validating the company's proprietary collagen technology for high-strength medical devices.

Company Intelligence Q&A

What is ExceeMatrix's core technology?

ExceeMatrix develops high-strength collagen medical devices using fibers derived from soft corals, which exhibit greater tensile strength than human connective tissue. This proprietary technology platform is used to create regenerative implants with superior mechanical properties.

What was a significant recent development for ExceeMatrix?

In February 2016, ExceeMatrix presented promising results for its ACL implant in an animal study, highlighting the potential of its high-tensile collagen technology for ligament and tendon repair.

What markets does ExceeMatrix target?

ExceeMatrix operates within the Health Tech & Life Sciences sector, focusing on medical technologies, biomaterials, and tissue regeneration for orthopedic applications.

When was ExceeMatrix founded?

ExceeMatrix was founded in March 2012.

What is the current employee size of ExceeMatrix?

ExceeMatrix currently has 1–10 employees.